Categories

Tag: Uncategorized

QUALITY/CONSUMERS: Wallace and some patient advocates

Information Therapy center chair Paul Wallace is from Kaiser Permanente, who quite logically would be interested in Ix.

He notes that the medical care cost, and the costs of poor health to employers far exceed the medical cost. (Absenteeism. etc)

He also notes that no consumer is involved in designing consumer directed health care. How do we get “skin in the game” not to be a blunt tool like managed care? And he explains that the revenue that would pay for the care of the 20% has left the system. let’s not use blunt tools to solve complex problems. That means using co-pays to access selective care, but not for pharmacy, well baby care, etc. And are there incentives to use information therapy in those decisions?

He has a vision of putting the patient centered care integrating this around patients not their diseases.

Then it’s on to two patient advocates. Sue Sheridan (who gave a harrowing speech last year that’s well worth re-reviewing) and Jesse Gruman from the Center from Advancement of Health. Sue has got the CDC to engage consumers in telling mothers about the risk that jaundice can cause brain damage. So eventually this fall they are putting out information that are right for new mothers—not about the disease but “how can my baby get hurt and how can I do something about it. Sue thinks fear is a gift that will motivate. Jesse is not so sure, but know that we need to arouse the anxiety just enough to give them something productive to do. Last year Jesse told us about “blunters and monitors.” In other words some people want the second opinion, want to know everything, but others want the doctor to tell them what to do. But there is no neutral health information. So the people trying to engage patients in health information have a major challenge. But Sue thinks that we should create the demand for patients to be engaged because if they’re more involved they’ll have better outcomes.

Jesse thinks that using marketing methodologies that retail et al use to make people buy stuff they don’t really want/need (e.g. data mining connections) needs to be used to deliver information therapy and make people integrate it in their life. We also need to tell people what we expect them to do.

One of the most interesting questions is from a Canadian who is telling about how consumer health information in his hospital (McMaster, in Hamilton Ontario) is worked out in conjunction with marketing academics. In the US he says that this stuff seems to be part of the marketing department, and be kept as proprietary information.

QUALITY/POLICY: Information Therapy conference, the employer coalition view

So as I warned you, I’m at the Information Therapy conference in Park City, Utah.

Andrew Webber from National Business Coalition on Health. Tries to come at Information Therapy from the point of view of an employer—but an employer who was brought up as the son of a Minister living in Spanish Harlem.

Employers are figuring it out….he thinks they can improve quality while controlling costs, and do it by making the health care system more functional. Andrew thinks that employers really want a more productive healthier workforce. He thinks that there should be metrics for how Wall Street looks at individual companies on the health/productivity issue. So we need better stories to get employers to realize that they need to get on board with improving this.

But overall employers want to point at providers and call it their fault! (for a bunch of reasons). But he thinks that employers can do better and they’ve been a big part of the problem. Employers have created a toxic payment system, that pays for poor quality of care.

Andrew wants employers to take responsibility for it! Their vision is health purchasing reform via value-based purchasing community by community.

His 4 pillars (of wisdom) are

1. Performance measurements2. Transparency and reporting3. Payment reform (he wants population-based not a fragmented FFS-based payment)4. Informed consumer choice

But you all know that, so let me show you a photo I took in a slot canyon in Arizona yesterday (taken on my Treo no less!)

Photo_092406_010

Meanwhile, Andrew thinks that this is all wrapped up in the change of Federal incentives (and the recent directive) to do more transparency and get consumer purchasing on the national radar.

Personally I get very nervous when Information Therapy gets wrapped up in the ideology of consumer-directed health care. Somehow he manages to think that what HHS and Leavitt is up to and what RWJ is supporting are consistent with each other! But he does make the reasonable point that Ix needs to somehow connect with the wider movements. I just hope it gets done as a neutral issue without getting into a real war over the ideology. If Ix gets wrapped up in that it will be shot in the crossfire.

PHARMA/POLITICS: When Democrats attack!

When Democrats attack, somehow it doesn’t convey the ferocity of the original series…but with Bush’s approval ratings going up as the price of gas comes down, the Democrats are issuing a Medicare drug report. Yup, they’ve noticed that there is both an election in November and that plenty of Part D participants are in the donut hole. And perhaps it’s about time to take the initiative back from the BS meme that “most people in Part D are happy so it must be a good thing/Republican votegetter, and the donut hole doesn’t really exist anyway.” The donut hole is the most obvious thing to go after, and the one that most seniors are concerned about, so here goes:

The analysis includes a breakdown by state showing how much more money residents would have to pay annually if they switched to a plan that had no doughnut hole. The nationwide average was $458. Residents of New Jersey would have to pay, on average, an additional $298. Residents of seven states would have to pay, on average, an additional $721. Those states are Iowa, Minnesota, Montana, North Dakota, Nebraska, South Dakota and Wyoming.”As this report shows, the opportunity to purchase plans that fill the hole is a mirage,” said Rep. Pete Stark, D-Calif. “Beneficiaries are no more able to afford expensive, full-coverage plans than minimum wage Americans are able to afford a Mercedes.”

On the other hand, they don’t seem to mention getting effective drug re-importation, even though that is banned by the legislation and over 80% of adults are in favor of it. And somehow they’ve managed to get the AP guys confused by the White House spin:

Democrats contend that one solution to filling the doughnut hole would be to let the government negotiate drug prices on behalf of beneficiaries, instead of having fragmented insurance companies doing that. Then, the government could use the savings achieved to do away with the gap. But Nelligan replied that all of the Democratic proposals that have been scored by the Congressional Budget Office had cost projections at least twice as high as the cost of the current drug benefit.

Hmm… it’s hard to imagine something costing more per benefit delivered than the current version of the Medicare Modernization Act, especially when the payoffs to employers, insurers and hospitals are counted in. And wasn’t there something about a certain government agency that already negotiates rather better on drug pricing that the Part D private plans, and yet somehow that information didn’t make it into this article? Oh yeah, there was.

QUALITY/HOSPITALS: Odd hospital stay ratings–only the good get mentioned?

In a vox populi column the SF Chronicle asked readers, How would you rate your last hospital stay? Funnily enough in every case when they had a good experience they mentioned the name of the hospital. If they had a bad experience, they didn’t call out its name.

Do people with bad experiences really tend to keep quiet about who did the dirty on them? Or is the Chronicle scared of pissing off advertisers? We report, you decide!

HOSPITALS/POLICY: Another hospital CEO calls for single payer

I put this up because you guys love this type of thing as an open thread. Albany Medical Center chief calls for hospital reform and single-payer system.  Albany Med Center is a monopoly non-profit provider, so it’ll do fine under single payer, but maybe not quite as well as it does now—but it’ll save a bundle not cahsing up its uninsured and charity care.

Oh, and by the way, just in case you were surprised the Senate Finance Committee has found that non-profit hospitals don’t really deliver any more charity care than for-profit ones, and as the list of Boston Hospital CEO salaries makes clear, their senior executives aren’t exactly beggaring themselves working there. Which confirms my conclusion that there’s little difference between them and that we should get rid of the distinction one way or another—and make them look like old fashioned public utilities. (Maggie Mahar is slightly more charitable about the non-profits, but not much)

 

PHARMA: Peter Rost’s confessions of a healthcare hitman

Rost_smallSo the book that Rost has been working on is out. (Here’s a very quick summary of his story I wrote back in March). It’s called The Whistleblower: Confessions of a Healthcare Hitman.

In contrast to John Mack’s review which calls it a little dull, I think it’s a very, very interesting tell-all and much more interesting than a fictionalized version would have been. It’s 200 pages and I devoured it in 2 hours. I am of course bitter that he stole my title, but we’ll let him off!

There are some problems with the book. First, Rost is a little late to the game on the series of corrupt practices that big Pharma has been involved in over the years. Marcia Angell did it better, and John Abramson gets better into the details. Rost’s chapter on that corruption (ch 19) is a big mess, because it presents several different types of malfeasance as being the same thing, whereas there are activities within big pharma that are way over the line, and others where the line may been approached but not crossed. In the latter case a pharma company may settle because it didn’t want to run the “death penalty risk” of not settling with an aggressive prosecutor and potentially being banned from government programs. The key point of that chapter gets a little lost—and that point is that breaking the law is a considered business risk for pharma and many other health care entities; more so when the “law” is unclear—which it often is.

However, the rewards are worth it and not just in pharma. After all St Barnabas paid a Medicare fine recently of $265m odd when it acknowledged overcharging some $630m! So crime does pay, and it pays in the health care world to fuzz up the notion of “crime”. (There is one great catch, which is that the front organization that nominated Rost for whiny whistleblower of the year was headed by a guy who’d done Federal time for Medicaid fraud). But I think the whole chapter could have been cut.

The other frustration with Rost’s book is that we don’t learn much about some key issues that are ongoing in the Genotropin suit and he hid the whole existence of the suit from the narrative, whereas I think it would have been better done to introduce it with everything else he was up to chronologically, as the rest of the book is organized. However, some of the lack of details is inevitable as that one has some while to play out…and at the moment it looks like Rost is facing an uphill battle. We do learn that there is or at least was an ongoing criminal investigation into the the Genotropin issue as well as Rost’s civil Qui Tam suit. That may have been public information but I didn’t know about it. But it’s a little like Wayne Rooney writing his autobiography aged 20!

Finally, Rost spends much time going on about how tough it is to be poor–but he was earning $500K a year until recently and must have some stashed away. He also doesn’t tell us how much he got out of Wyeth (and maybe he can’t under that settlement) even though he details in the book that apparently many Wyeth execs had to settle with their local tax authorities at great personal pain.

But in any event the book is mostly about what happened when Pfizer took over Pharmacia, and has some interesting revelations about how Pharmacia may have juiced its earnings to indue Pfizer to overpay. That, of course, wouldn’t exactly have been an unknown act (Enron? Worldcom?)—although Pfizer today is at pains to say that the SEC has already investigated this and found it baseless. Not that corporate America has any sway over the SEC, the DOJ or anything, unless your name is the same as the leader of the Senate’s, or the current President’s!

Other than those quibbles I genuinely found this a terrific page turner. For sure it’s written in a self-sympathetic manner. Well what did you expect? There’s no doubt that Rost enjoys pissing people off, and knows his way around some Internet tracking tools that few corporate suits understand. We also of course don’t hear Pharmacia/Pfizer’s side of the story—but it’s going to be very interesting if they try to explain that Rost was behind the Genotorpin scheme himself. Because their defense must be either that or he’s made the whole thing up. (And if they really are withholding a database of contracts from the DOJ, as Rost says, I assume that they’ll be found out one way or another).

But it’s a great read straight from the horse’s mouth of a guy fighting a massive corporation with the weapons he has at his disposal. And very entertaining too. I know that it will be read alot, especially in the pharma business! And it’s yet more embarrassment for a big corporation that had a knee-jerk reaction to a problem that it could have solved easily by a) coming clean and b) buying off the squeaky wheel.

It reminds a great deal of the Thatcher government that could have got rid of the whole Spycatcher scandal by paying the ex-spy his pension, and instead landed itself in deep doo-doo, while helping the ex-spy turned author Wright sell a ton more books!

BLOGS: Book reviews and new sponsor

For those of you who may have missed it because it was posted in a slow week before Labor day—here’s a link to my review of two books

Winners Take All – The 9 Fundamental Rules of High Tech Strategy and On Track to Quality. Both well worth a read.

Meanwhile, will you welcome please a new sponsor to THCB. Appearing in the “Sponsored Links” category is 1on1Health, a consumer health information site sponsored by GlaxoSmithKline. They’re focusing first on Anxiety Disorder, so don’t be surprised when you see the link on the right.

And of course if you want information about reaching the smartest and largest audience in health care blogging, it’s all just an email away.

assetto corsa mods